Drugs / Ceftaroline
Ceftaroline
Trials 20
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 18 trials · 1 met primary | ||||||
| Phase 1 | NCT03025841 | Dec 2016 → Dec 2017 | pneumonia | Poitiers University Hospital | Completed | No outcome recorded |
| Phase 1 | NCT02600793 | Aug 2016 → Dec 2019 | — | Basim Asmar | Unknown | No outcome recorded |
| Phase 1 | NCT02806882 | Apr 2015 → Oct 2016 | meningitis | Centre Hospitalier Universitaire Dijon | Completed | No outcome recorded |
| Phase 1 | NCT01648127 | Jul 2012 → Feb 2013 | — | Keith A. Rodvold | Completed | No outcome recorded |
| Phase 1 | NCT01577589 | Apr → Sep 2012 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01458743 | Oct 2011 → Apr 2012 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01290900 | Feb → May 2011 | — | Pfizer | Completed | Met primary |
| Phase 1 | NCT00633126 | Mar 2008 → Feb 2009 | infectious disease | Forest Laboratories | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00633152 | Feb → Jul 2008 | bacterial infectious disease | Forest Laboratories | Completed | No outcome recorded |
| Phase 34 trials · 2 met primary | ||||||
| Phase 3 | NCT02735707 | Apr 2016 → Feb 2026 overdue | pneumonia | UMC Utrecht | Recruiting | Mixed |
| Phase 3 | NCT01605864 | May 2012 → Mar 2013 | bacterial pneumonia | Albany Medical College | Completed | No outcome recorded |
| Phase 3 | NCT00423657 | Mar → Dec 2007 | bacterial infectious disease | Forest Laboratories | Completed | Met primary |
| Phase 3 | NCT00424190 | Feb → Nov 2007 | bacterial infectious disease | Forest Laboratories | Completed | Met primary |
| Phase 47 trials | ||||||
| Phase 4 | NCT07376889 | Feb 2026 → Jan 2029 expected | staphylococcus aureus infection | Intermountain Health Care, Inc. | Recruiting | No outcome recorded |
| Phase 4 | NCT07148960 | Sep 2025 → Jul 2027 expected | staphylococcus aureus infection | West Virginia University | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT05156437 | Mar 2022 → Oct 2024 | endocarditis | West Virginia University | Terminated | No outcome recorded |
| Phase 4 | NCT02937181 | Dec 2016 → Oct 2018 | — | Olayemi Osiyemi MD | Unknown | No outcome recorded |
| Phase 4 | NCT02660346 | Nov 2015 → Sep 2017 | bacterial infectious disease | Sharp HealthCare | Completed | No outcome recorded |
| Phase 4 | NCT02307006 | Jan 2015 → Dec 2016 | — | University of Cincinnati | Unknown | No outcome recorded |
| Phase 4 | NCT02005068 | Apr 2013 → Jul 2014 | infective arthritis, osteomyelitis | Orlando Health, Inc. | Withdrawn | No outcome recorded Stop: Enrollment |
| Comparator or background therapy7 trials | ||||||
| Phase 1 | NCT07228702 Background | Jan 2026 → Oct 2027 expected | pulmonary non-tuberculous mycobacterial infection | Vancouver Coastal Health | Enrolling by invitation | No outcome recorded |
| Phase 2 | NCT01756924 Comparator | Dec 2012 → Jul 2014 | periprosthetic joint infection | Arrevus Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT06336824 Comparator | Jun 2024 → May 2025 overdue | staphylococcus aureus infection | Clinical Research Centre, Malaysia | Recruiting | No outcome recorded |
| Phase 4 | NCT05977868 Comparator | Aug 2023 → Feb 2025 | digestive system infectious disorder | West Virginia University | Terminated | No outcome recorded |
| Phase 4 | NCT01524302 Comparator | Feb 2012 → May 2014 | bacterial pneumonia | Gary E. Stein, Pharm.D. | Completed | No outcome recorded |
| Phase 4 | NCT02582203 Comparator | Feb 2012 → May 2016 | skin disorder caused by infection, staphylococcal infection | Wayne State University | Completed | No outcome recorded |
| Phase 4 | NCT01734694 Comparator | Oct 2011 → Sep 2012 | bacterial infectious disease, endocarditis, nosocomial infection, osteomyelitis | Henry Ford Health System | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2012-08-28 | AstraZeneca | Regulatory European Commission approves ZINFORO™ (ceftaroline fosamil) for adult patients with serious skin infections or community acquired pneumonia astrazeneca.com ↗
AstraZeneca today announced that the European Commission has granted Marketing Authorisation to ZINFORO™ (ceftaroline fosamil), a new intravenous cephalosporin antibiotic, for the treatment of adult patients with complicated Skin and Soft Tissue Infections (cSSTI) or Community Acquired Pneumonia (CAP). |
| 2012-06-22 | AstraZeneca | Regulatory Zinforo (ceftaroline fosamil) receives positive CHMP opinion in the European Union for the treatment of patients with serious skin infections or community acquired pneumonia astrazeneca.com ↗
The CHMP's positive opinion will now be reviewed by the European Commission, which has the authority to approve medicines for the European Union. |
All press releases naming this drug 2 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 30 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ceftaroline | “Participant given IV daptomycin plus ceftaroline dosing per standard of care.” NCT07148960 ↗ |
| Known as | ceftaroline fosamil | “single doses of IV ceftaroline fosamil 1,500 mg with avibactam 2,000 mg” PMID 24150927 ↗ Oct 20132“In patients, ceftaroline is given as a prodrug, ceftaroline fosamil.” NCT03025841 ↗ “Drug: Ceftaroline fosamil” NCT02806882 ↗ |
| Known as | Zinforo | “Population Pharmacokinetic (PK) Study of Zinforo (Ceftaroline) in Critical Care Patients With Early-onset Pneumonia and Normal or Augmented Renal Clearance” NCT03025841 ↗ |
| Modality | Other / unclassified | “Ceftaroline fosamil is a new-generation, parenteral cephalosporin” PMID 21115456 ↗ Nov 2010 |
| Route | Intravenous | “ceftaroline fosamil [600 mg q12h by 1-h i.v. infusion” PMID 34922058 ↗ Dec 2021 |